Multiple endocrine neoplasia type 2: An overview

Multiple endocrine neoplasia type 2 is historically composed of three clinical subtypes, all of which are associated with germline mutations in the RET proto-oncogene. Multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and multiple endocrine neoplasia type 2B are collectively associated with a 70–100% risk of medullary thyroid carcinoma by age 70 years. Pheochromocytomas are identified in 50% of individuals with multiple endocrine neoplasia type 2A and multiple endocrine neoplasia type 2B. Furthermore, those with multiple endocrine neoplasia type 2A have a 20–30% risk for primary hyperparathyroidism. Individuals with multiple endocrine neoplasia type 2B often have distinct physical features including mucosal neuromas of the lips and tongue, medullated corneal nerve fibers, ganglioneuromatosis of the gastrointestinal tract, distinctive facies with enlarged lips, and a “Marfanoid” body habitus. Clinical recognition and accurate diagnosis of individuals and families who are at risk of harboring a germline RET mutation is critical for the prevention and management of potentially life-threatening neoplasms. This overview summarizes the clinical description of multiple endocrine neoplasia type 2, diagnosis and testing strategies, management and surveillance, and differential diagnosis for other related syndromes.

[1]  P. V. van Diest,et al.  Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. , 2002, The Journal of clinical endocrinology and metabolism.

[2]  A. Pinchera,et al.  RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. , 2007, The Journal of clinical endocrinology and metabolism.

[3]  B. Pasini,et al.  Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.

[4]  P. Komminoth,et al.  Review of multiple endocrine neoplasia type 2A in children: therapeutic results of early thyroidectomy and prognostic value of codon analysis. , 2003, Pediatrics.

[5]  J. Celli,et al.  Association of multiple endocrine neoplasia type 2 and Hirschsprung disease , 1998, Journal of internal medicine.

[6]  D. Neuberg,et al.  Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation , 1999, Oncogene.

[7]  J. Norton,et al.  Multiple endocrine neoplasia type 2B--genetic basis and clinical expression. , 2000, Surgical oncology.

[8]  H. Gharib,et al.  Medullary thyroid cancer: management guidelines of the American Thyroid Association. , 2009, Thyroid : official journal of the American Thyroid Association.

[9]  R. A. Decker,et al.  Update on the MEN 2A c804 RET mutation: is prophylactic thyroidectomy indicated? , 2000, Surgery.

[10]  K. Pacak,et al.  Adverse Drug Reactions in Patients with Phaeochromocytoma , 2007, Drug safety.

[11]  S. Gruber,et al.  Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. , 2009, Thyroid : official journal of the American Thyroid Association.

[12]  S. Baylin,et al.  Familial medullary thyroid carcinoma without associated endocrinopathies: A distinct clinical entity , 1986, The British journal of surgery.

[13]  P. Parrilla,et al.  Pheochromocytoma in MEN 2A Syndrome. Study of 54 Patients , 2008, World Journal of Surgery.

[14]  K. Heimdal,et al.  [Prophylactic thyroidectomy in carriers of RET oncogene mutation carriers]. , 2000, Tidsskrift for Den Norske Laegeforening.

[15]  I. Ilias,et al.  Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome. , 2009, Endocrine regulations.

[16]  N. Asai,et al.  Mechanism of ret dysfunction by Hirschsprung mutations affecting its extracellular domain. , 1996, Human molecular genetics.

[17]  C. Eng,et al.  Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. , 2010, The Journal of clinical endocrinology and metabolism.

[18]  T. Matise,et al.  A gene for Hirschsprung disease (megacolon) in the pericentromeric region of human chromosome 10 , 1993, Nature Genetics.

[19]  L. Mulligan,et al.  Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis , 2000, Journal of medical genetics.

[20]  B. Ponder,et al.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A , 1993, Nature.

[21]  Jeffrey E. Lee,et al.  Failure to Recognize Multiple Endocrine Neoplasia 2B: More Common Than We Think? , 2007, Annals of Surgical Oncology.

[22]  B. Ponder,et al.  Germline mutation of RET codon 883 in two cases of de novo MEN 2B , 1997, Oncogene.

[23]  G. Romeo,et al.  A Cys634Gly substitution of the RET proto‐oncogene in a family with recurrence of multiple endocrine neoplasia type 2A and cutaneous lichen amyloidosis , 1997, Clinical genetics.

[24]  L. Mulligan,et al.  Germline dinucleotide mutation in codon 883 of the RET proto-oncogene in multiple endocrine neoplasia type 2B without codon 918 mutation. , 1997, The Journal of clinical endocrinology and metabolism.

[25]  Douglas B. Evans,et al.  Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. , 2004, The Journal of clinical endocrinology and metabolism.

[26]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[27]  D. Pfister,et al.  Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  D. Clayton,et al.  Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC , 1994, Nature Genetics.

[29]  J. Norton,et al.  Medullary thyroid carcinoma in children with multiple endocrine neoplasia types 2A and 2B. , 1996, Journal of pediatric surgery.

[30]  J. Carrasquillo,et al.  Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma , 2008, Journal of Nuclear Medicine.

[31]  R. Hinze,et al.  Papillary thyroid carcinoma in patients with RET proto-oncogene germline mutation. , 2002, Thyroid : official journal of the American Thyroid Association.

[32]  al. et,et al.  Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B , 1995, Science.

[33]  J. Moley,et al.  Surgical treatment of medullary thyroid carcinoma * , 2003, Journal of internal medicine.

[34]  Martin Fassnacht,et al.  Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10 , 2011, Human mutation.

[35]  Masahide Takahashi,et al.  Co‐segregation of MEN2 and Hirschsprung's disease: The same mutation of RET with both gain and loss‐of‐function? , 1999 .

[36]  V. Rohmer,et al.  Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study. , 2001, European journal of endocrinology.

[37]  C Eng,et al.  The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. , 1996, JAMA.

[38]  G. Chiappetta,et al.  RET activation and clinicopathologic features in poorly differentiated thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[39]  C. Richards,et al.  Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.

[40]  D. Pertsemlidis,et al.  Pheochromocytoma: inherited associations, bilaterality, and cortex preservation. , 2000, Surgery.

[41]  Mcmahon,et al.  Molecular genetic analysis of von Hippel–Lindau disease , 1998, Journal of internal medicine.

[42]  M. Santoro,et al.  The RET receptor: function in development and dysfunction in congenital malformation. , 2001, Trends in genetics : TIG.

[43]  B. Ponder,et al.  Guidelines for diagnosis and therapy of MEN type 1 and type 2. , 2001, The Journal of clinical endocrinology and metabolism.

[44]  C. Fisher,et al.  Diffuse ganglioneuromatosis in small intestine associated with neurofibromatosis type 1. , 2009, Annals of diagnostic pathology.

[45]  B. Alford,et al.  Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. , 1989, Annals of internal medicine.

[46]  S. Bézieau,et al.  Germline RET V804M mutation associated with multiple endocrine neoplasia type 2A , 2004, The British journal of surgery.

[47]  R. DeLellis.  Pathology and genetics of tumours of endocrine organs , 2004 .

[48]  J. Weissenbach,et al.  A gene for Hirschsprung disease maps to the proximal long arm of chromosome 10 , 1993, Nature Genetics.

[49]  H. Dralle,et al.  Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside , 2006, Molecular and Cellular Endocrinology.

[50]  R. Hofstra,et al.  Acceptable age for prophylactic surgery in children with multiple endocrine neoplasia type 2a. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[51]  G M Lenoir,et al.  Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma. Le Groupe d'Etude des Tumeurs a Calcitonine. , 1997, American journal of human genetics.

[52]  G. Lenoir,et al.  Variable expressivity of familial medullary thyroid carcinoma (FMTC) due to a RET V804M (GTG-->ATG) mutation. , 2000, Surgery.

[53]  V. Livolsi.  C cell hyperplasia/neoplasia. , 1997, The Journal of clinical endocrinology and metabolism.

[54]  H. Dralle,et al.  Early malignant progression of hereditary medullary thyroid cancer. , 2003, The New England journal of medicine.

[55]  Charis Eng,et al.  Cancer phenomics: RET and PTEN as illustrative models , 2007, Nature Reviews Cancer.

[56]  H. Dralle,et al.  Pheochromocytoma in multiple endocrine neoplasia type 2: European study , 1995, Journal of internal medicine.

[57]  M. Wiench,et al.  Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. A. Decker,et al.  Hirschsprung disease in MEN 2A: increased spectrum of RET exon 10 genotypes and strong genotype-phenotype correlation. , 1998, Human molecular genetics.

[59]  J. Schipper,et al.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[60]  P. Beck‐Peccoz,et al.  Frequent association between MEN 2A and cutaneous lichen amyloidosis , 2003, Clinical endocrinology.

[61]  H. Jacene,et al.  Recurrent or residual hyperparathyroidism and thyroid cancer effectively evaluated with scintigraphy. , 2008, Otolaryngologic clinics of North America.

[62]  M. Santoro,et al.  Minireview: RET: normal and abnormal functions. , 2004, Endocrinology.

[63]  C. Eng,et al.  Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. , 1998, The Journal of clinical endocrinology and metabolism.

[64]  P. Beck‐Peccoz,et al.  Multigenerational familial medullary thyroid cancer (FMTC): evidence for FMTC phenocopies and association with papillary thyroid cancer , 2002, Clinical endocrinology.

[65]  P. Goodfellow,et al.  Parent-of-origin effects in multiple endocrine neoplasia type 2B. , 1994, American journal of human genetics.

[66]  R. Simó,et al.  V804M RET mutation and familial medullary thyroid carcinoma: report of a large family with expression of the disease only in the homozygous gene carriers. , 2002, Surgery.

[67]  K. Nathanson,et al.  Pheochromocytoma: the expanding genetic differential diagnosis. , 2003, Journal of the National Cancer Institute.

[68]  Elena S. Di Martino,et al.  Identification of the Cys634->Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis , 1994, Journal of endocrinological investigation.

[69]  N. Asai,et al.  Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. , 1998, Journal of internal medicine.

[70]  D. Easton,et al.  RISK ESTIMATION AND SCREENING IN FAMILIES OF PATIENTS WITH MEDULLARY THYROID CARCINOMA , 1988, The Lancet.

[71]  K. Nakao,et al.  Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin , 1996, Journal of Molecular Medicine.

[72]  J. Schipper,et al.  Clinical features of paraganglioma syndromes. , 2009, Skull base : official journal of North American Skull Base Society ... [et al.].

[73]  A. Maia,et al.  RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. , 2003, The Journal of clinical endocrinology and metabolism.

[74]  P. Goodfellow,et al.  Novel germline RET proto-oncogene mutations associated with medullary thyroid carcinoma (MTC): mutation analysis in Japanese patients with MTC , 1997, Oncogene.

[75]  M. Pierotti,et al.  The familial medullary thyroid carcinoma-associated RET E768D mutation in a multiple endocrine neoplasia type 2A case. , 2005, Surgery.

[76]  P. Parrilla,et al.  Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma , 1998, Clinical endocrinology.

[77]  Susan S. Taylor,et al.  RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. , 2006, Cancer research.

[78]  A. Munnich,et al.  Diversity of RET proto-oncogene mutations in familial and sporadic Hirschsprung disease. , 1995, Human molecular genetics.

[79]  H. Lehnert,et al.  Phaeochromocytoma, new genes and screening strategies , 2006, Clinical endocrinology.

[80]  C. Eng,et al.  Frequent gastrointestinal polyps and colorectal adenocarcinomas in a prospective series of PTEN mutation carriers. , 2010, Gastroenterology.

[81]  B. Ponder,et al.  Mutations of the RET proto-oncogene in Hirschsprung's disease , 1994, Nature.

[82]  A. Munnich,et al.  Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease. , 1998, The Journal of clinical investigation.

[83]  C. Eng,et al.  Prevalence and parental origin of de novo RET mutations in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma [4] , 1997 .

[84]  Dilley,et al.  Surgical management of patients with persistent or recurrent medullary thyroid cancer , 1998, Journal of internal medicine.

[85]  C. Ugolini,et al.  RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) , 2011, Clinical endocrinology.

[86]  C. Eng,et al.  PTEN hamartoma tumor syndrome: An overview , 2009, Genetics in Medicine.

[87]  C. Eng,et al.  Adrenal and extra-adrenal pheochromocytomas in a family with germline RET V804L mutation. , 1999, JAMA.

[88]  M. Maranghi,et al.  Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. , 2007, The Journal of clinical endocrinology and metabolism.

[89]  John P. Bilezikian,et al.  CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2 , 2001 .

[90]  Alexander L. Shifrin,et al.  One hundred and seven family members with the rearranged during transfection V804M proto-oncogene mutation presenting with simultaneous medullary and papillary thyroid carcinomas, rare primary hyperparathyroidism, and no pheochromocytomas: is this a new syndrome--MEN 2C? , 2010, Surgery.

[91]  L. Mulligan,et al.  Diverse phenotypes associated with exon 10 mutations of the RET proto-oncogene. , 1994, Human molecular genetics.

[92]  H. Neumann,et al.  Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma. , 2006, The New England journal of medicine.

[93]  A. Miyauchi,et al.  Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation , 1999, Japanese journal of cancer research : Gann.

[94]  S. Richard,et al.  Head and neck paragangliomas in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. , 2009, The Journal of clinical endocrinology and metabolism.

[95]  Rong Mao,et al.  Multiple endocrine neoplasia type 2 RET protooncogene database: Repository of MEN2‐associated RET sequence variation and reference for genotype/phenotype correlations , 2009, Human mutation.

[96]  E S Husebye,et al.  Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. , 2001, American journal of human genetics.

[97]  G. Chiappetta,et al.  RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[98]  Adopted on March.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  D. Bredesen,et al.  The RET proto‐oncogene induces apoptosis: a novel mechanism for Hirschsprung disease , 2000, The EMBO journal.

[100]  B. Ponder,et al.  Germline RET codon 918 mutation in apparently isolated intestinal ganglioneuromatosis. , 1998, The Journal of clinical endocrinology and metabolism.

[101]  I. Ilias,et al.  Biochemical diagnosis, localization and management of pheochromocytoma: focus on multiple endocrine neoplasia type 2 in relation to other hereditary syndromes and sporadic forms of the tumour , 2005, Journal of internal medicine.

[102]  Jeffrey E. Lee,et al.  Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. , 2003, Archives of surgery.

[103]  E. Mazzaferri,et al.  Diagnosis and management of medullary thyroid carcinoma. , 2004, Clinics in laboratory medicine.